Democrats such as Elizabeth Warren had their eye on business and the working class during the first 2020 presidential primary debate in Miami.2020 Electionsread more
The issue over health insurance marked the first stark divide among the candidates, and sparked a heated back-and-forth between many of the candidates on stage.Politicsread more
Huawei's legal chief told CNBC that the company makes "solutions for civil use."Technologyread more
Four candidates mentioned China — but none of the Democratic contenders brought up trade in the debate.Politicsread more
In a strategy to draw attention away from Wednesday's Democratic debate, President Donald Trump's reelection campaign bought out YouTube's "masthead," the leading...2020 Electionsread more
The Federal Aviation Administration said on Wednesday that is has found an issue with the Boeing 737 Max that the manufacturer must address before it lifts the grounding...Airlinesread more
The collapse of the deal potentially ended Sinclair's hopes of building a national conservative-leaning TV powerhouse that might have rivaled Fox News.Mediaread more
Huawei legal chief Song Liuping told CNBC that the company is in the "early phase" of talks with Verizon over paying royalties.Technologyread more
Virginia Sen. Mark Warner breaks down the idea behind a bipartisan bill he introduced to provide more transparency in Big Tech.Technologyread more
Tesla is working on new battery cell designs, and a way to make their own cells, with R&D teams in a lab near its car plant in Fremont, California.Technologyread more
Wi-Fi 6 will be the next-generation wireless standard. Along with 5G, it will represent the next big shift in connectivity and data, said Irving Tan, senior vice president and...Shaping the futureread more
With the biotech sector on pace for one of its worse days, analysts were divided Monday on whether the sell-off was nothing but "political noise" or a sign of correction.
"We're seeing some global concerns, you're seeing the entire market come off, and then the commentary from Hillary [Clinton] about pricing has absolutely fueled the fire here," David Seaburg, head of sales and trading at Cowen & Co. said Monday on CNBC's "Power Lunch." "We're seeing some large-cap names being totally dismantled for the wrong reasons."
The Nasdaq closed down 3 percent Monday afternoon after pressure from the biotechnology sector pushed stocks lower. One biotech ETF, the iShares Nasdaq biotechnology ETF (IBB), was priced more than 20 percent lower than its 52-week high.
The plunge came after a week of losses as policymakers scrutinized the sector.
Reports of large price hikes on pharmaceutical products like Daraprim sparked outrage from presidential candidate Clinton last week. Democrats called Monday for a review of other biotechnology companies such as Valeant.
With any legal changes to drug regulation at least three years away, Seaburg institutional investors have not been hit with the same panic that has retail investors selling their shares. He also said there is still growth opportunity and innovation in the biotech sector.
"You're looking at a setup ... that could be one of the best buying opportunities for the whole year," Seaburg said.
Jerry Castellini, president and CIO of CastleArk Management, was more bearish, and said he expects several months of consolidation in the industry.
Rather than buy on the dip, Castellini told CNBC he would "step away and let the dust settle" from the biotech fallout.